VRTX — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

1.65

Margin Of Safety %

Put/Call OI Ratio

0.85

EPS Next Q Diff

0.48

EPS Last/This Y

3.68

EPS This/Next Y

2.42

Price

434.55

Target Price

554.07

Analyst Recom

1.57

Performance Q

-9.67

Upside

-14.6%

Beta

0.3

Ticker: VRTX

22 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-04-23	VRTX	435.35	0.87	6.73	41765
2026-04-24	VRTX	430.23	0.88	1.39	42332
2026-04-27	VRTX	425.98	0.87	1.70	41591
2026-04-28	VRTX	430.14	0.87	2.94	42381
2026-04-29	VRTX	423.42	0.89	0.40	43009
2026-04-30	VRTX	427.34	0.88	2.67	43775
2026-05-01	VRTX	424.02	0.86	2.42	44123
2026-05-04	VRTX	439.5	0.89	0.90	44355
2026-05-05	VRTX	424.33	0.93	1.88	49061
2026-05-06	VRTX	427.6	0.97	0.74	51314
2026-05-07	VRTX	425	0.96	0.79	51494
2026-05-08	VRTX	429.8	0.96	1.15	51702
2026-05-11	VRTX	435.19	0.90	0.45	46701
2026-05-12	VRTX	448.46	0.90	0.67	46971
2026-05-13	VRTX	453.26	0.89	0.53	47952
2026-05-14	VRTX	450.59	0.88	1.76	49459
2026-05-15	VRTX	436.89	0.88	0.35	50659
2026-05-18	VRTX	436.89	0.86	0.64	48313
2026-05-19	VRTX	434.32	0.86	0.35	48891
2026-05-20	VRTX	430.03	0.85	0.63	49671
2026-05-21	VRTX	433.71	0.84	1.28	50064
2026-05-22	VRTX	434.12	0.85	0.98	50964
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

22 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-04-23	VRTX	435.22	5.7	625.5	19.04
2026-04-24	VRTX	430.24	5.7	594.6	19.04
2026-04-27	VRTX	425.97	5.7	600.8	19.04
2026-04-28	VRTX	430.17	5.7	710.7	19.04
2026-04-30	VRTX	427.29	5.7	687.9	19.04
2026-05-01	VRTX	423.84	6.0	589.2	19.09
2026-05-04	VRTX	429.98	6.0	714.0	19.09
2026-05-05	VRTX	424.29	6.1	597.8	19.09
2026-05-06	VRTX	427.57	6.1	712.7	19.09
2026-05-07	VRTX	424.83	5.1	448.0	19.18
2026-05-08	VRTX	429.78	5.1	558.6	19.18
2026-05-11	VRTX	435.27	5.1	566.6	19.19
2026-05-12	VRTX	448.40	4.9	664.4	19.17
2026-05-13	VRTX	453.10	4.9	555.7	19.17
2026-05-14	VRTX	450.49	4.9	465.2	19.17
2026-05-15	VRTX	436.97	4.9	331.9	19.17
2026-05-18	VRTX	436.74	4.8	493.8	19.17
2026-05-19	VRTX	434.26	4.8	465.1	19.17
2026-05-20	VRTX	430.27	4.8	445.0	19.17
2026-05-21	VRTX	433.54	4.6	536.2	19.14
2026-05-22	VRTX	434.55	4.6	509.4	19.14
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-04-23	VRTX	-30.90	-0.06	1.59
2026-04-24	VRTX	-30.90	-0.06	1.59
2026-04-27	VRTX	-30.90	-0.42	1.71
2026-04-28	VRTX	-30.90	-0.42	1.71
2026-04-29	VRTX	-30.90	-0.42	1.71
2026-04-30	VRTX	-30.90	-0.42	1.71
2026-05-01	VRTX	-30.90	-0.42	1.71
2026-05-04	VRTX	-30.90	-0.51	1.71
2026-05-05	VRTX	-30.90	-0.51	1.71
2026-05-06	VRTX	-30.99	-0.51	1.71
2026-05-07	VRTX	-30.99	-0.51	1.71
2026-05-08	VRTX	-31.04	-0.51	1.71
2026-05-11	VRTX	-31.04	-0.69	1.71
2026-05-12	VRTX	-31.04	-0.69	1.65
2026-05-13	VRTX	-31.04	-0.69	1.65
2026-05-14	VRTX	-31.04	-0.69	1.65
2026-05-15	VRTX	-31.51	-0.69	1.65
2026-05-18	VRTX	-26.30	-0.88	1.65
2026-05-19	VRTX	-26.30	-0.88	1.65
2026-05-20	VRTX	-26.21	-0.88	1.65
2026-05-21	VRTX	-26.21	-0.88	1.65
2026-05-22	VRTX	-32.14	-0.88	1.65
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

4.47

Avg. EPS Est. Current Quarter

4.73

Avg. EPS Est. Next Quarter

4.95

Insider Transactions

-32.14

Institutional Transactions

-0.88

Beta

0.3

Average Sales Estimate Current Quarter

3210

Average Sales Estimate Next Quarter

3343

Fair Value

467.53

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

16.4

Max Drawdown 5-Year %

-29.1

Target Price

554.07

P/E

25.76

Forward P/E

20.1

PEG

1.98

P/S

8.94

P/B

5.7

P/Free Cash Flow

29.72

EPS

16.87

Average EPS Est. Cur. Y

19.14

EPS Next Y. (Est.)

21.56

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

35.15

Relative Volume

1.35

Return on Equity vs Sector %

-4.7

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

0.1

EBIT Estimation

509.4

◆ VRTX Healthcare

$434.52

📉

Swing / Pullback

Buy the dip on strong trends

WEAK

Trend

10/20

Pullback

17/25

Volume

3/15

Valuation

16/20

TP/AR

3/10

Options

4/10

RSI

48.1

Range 1M

49.4%

Sup Dist

1.5%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

4/25

Growth

15/30

Estimates

8/20

Inst/Vol

3/15

Options

2/10

EPS Yr

EPS NY

11.9%

52W%

49.3%

💎

Long-Term Value

Quality companies, undervalued

WEAK

🟡 HOLD +12.4% upside

Quality

23/30

Valuation

7/30

Growth

10/25

Stability

7/10

LT Trend

1/5

Upside

+12.4%

Quality

MoS

Vertex Pharmaceuticals Incorpor

Sector: Healthcare

Industry: Biotechnology

Employees: 6400

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

VRTX

Latest News

—

Caricamento notizie per VRTX…

stock quote shares VRTX – Vertex Pharmaceuticals Incorporated Stock Price stock today

news today VRTX – Vertex Pharmaceuticals Incorporated stock forecast ,stock prediction 2023 2024 2025

marketwatch VRTX – Vertex Pharmaceuticals Incorporated yahoo finance google finance

stock history VRTX – Vertex Pharmaceuticals Incorporated invest stock market

stock prices VRTX premarket after hours

ticker VRTX fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: VRTX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y